

Julia C Gage

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/124304/publications.pdf>

Version: 2024-02-01

119
papers

5,317
citations

66343

42
h-index

95266

68
g-index

122
all docs

122
docs citations

122
times ranked

4341
citing authors

#	ARTICLE	IF	CITATIONS
1	The development of “automated visual evaluation” for cervical cancer screening: The promise and challenges in adapting deep learning for clinical testing. <i>International Journal of Cancer</i> , 2022, 150, 741-752.	5.1	29
2	Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management. <i>Journal of the National Cancer Institute</i> , 2022, 114, 845-853.	6.3	12
3	Contribution of Etiologic Cofactors to CIN3+ Risk Among Women With Human Papillomavirus “Positive Screening Test Results. <i>Journal of Lower Genital Tract Disease</i> , 2022, 26, 127-134.	1.9	9
4	Redesign of a rapid, low-cost HPV typing assay to support risk-based cervical screening and management. <i>International Journal of Cancer</i> , 2022, 151, 1142-1149.	5.1	12
5	Comparison of immediate colposcopy, repeat conventional cytology and high-risk human papillomavirus testing for the clinical management of atypical squamous cells of undetermined significance cytology in routine health services of Medellin, Colombia: The ASCUS-COL trial. <i>International Journal of Cancer</i> , 2021, 148, 1394-1407.	5.1	5
6	A proposed new generation of evidence-based microsimulation models to inform global control of cervical cancer. <i>Preventive Medicine</i> , 2021, 144, 106438.	3.4	20
7	Network Visualization and Pyramidal Feature Comparison for Ablative Treatability Classification Using Digitized Cervix Images. <i>Journal of Clinical Medicine</i> , 2021, 10, 953.	2.4	7
8	Rethinking Cervical Cancer Screening in Brazil Post COVID-19: A Global Opportunity to Adopt Higher Impact Strategies. <i>Cancer Prevention Research</i> , 2021, 14, 919-926.	1.5	5
9	Moving towards a strategy to accelerate cervical cancer elimination in a high-burden city “Lessons learned from the Amazon city of Manaus, Brazil. <i>PLoS ONE</i> , 2021, 16, e0258539.	2.5	3
10	Development of a Large Biorepository of Cervical Specimens for the Improving Risk Informed HPV Screening Study (IRIS). <i>Journal of Clinical Virology</i> , 2021, 145, 105014.	3.1	2
11	The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0865.2021.	2.5	3
12	The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador. <i>Preventive Medicine</i> , 2020, 131, 105931.	3.4	9
13	Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage. <i>Infectious Agents and Cancer</i> , 2020, 15, 60.	2.6	27
14	A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. <i>EClinicalMedicine</i> , 2020, 22, 100293.	7.1	109
15	Outcomes for Step-Wise Implementation of a Human Papillomavirus Testing-Based Cervical Screen-and-Treat Program in El Salvador. <i>JCO Global Oncology</i> , 2020, 6, 1519-1530.	1.8	12
16	Association of HPV35 with cervical carcinogenesis among women of African ancestry: Evidence of viral-host interaction with implications for disease intervention. <i>International Journal of Cancer</i> , 2020, 147, 2677-2686.	5.1	44
17	Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 132-143.	1.9	116
18	A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 144-147.	1.9	48

#	ARTICLE	IF	CITATIONS
19	Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 383-394.	2.2	4
20	The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador. International Journal of Gynecology and Obstetrics, 2019, 145, 40-46.	2.3	20
21	Evaluation of two alternative ablation treatments for cervical pre-cancer against standard gas-based cryotherapy: a randomized non-inferiority study. International Journal of Gynecological Cancer, 2019, 29, 851-856.	2.5	6
22	Evaluation of Risk-based Colposcopy for Cervical Precancers Detection in the ASCUS LSIL Triage Study [40B]. Obstetrics and Gynecology, 2019, 133, 31S-31S.	2.4	0
23	Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results. Journal of the National Cancer Institute, 2019, 111, 820-827.	6.3	20
24	Perceived Susceptibility to Cervical Cancer among African American Women in the Mississippi Delta: Does Adherence to Screening Matter?. Women's Health Issues, 2019, 29, 38-47.	2.0	12
25	5-Year Prospective Evaluation of Cytology, Human Papillomavirus Testing, and Biomarkers for Detection of Anal Precancer in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men. Clinical Infectious Diseases, 2019, 69, 631-638.	5.8	29
26	An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. Journal of the National Cancer Institute, 2019, 111, 923-932.	6.3	249
27	Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing. Journal of Clinical Microbiology, 2018, 56, .	3.9	18
28	Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology. Journal of the National Cancer Institute, 2018, 110, 1222-1228.	6.3	12
29	Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21-39 Years. Cancer Prevention Research, 2018, 11, 165-170.	1.5	26
30	Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. Journal of the National Cancer Institute, 2018, 110, 501-508.	6.3	116
31	Effects of Maintenance on Quality of Performance of Cryotherapy Devices for Treatment of Precancerous Cervical Lesions. Journal of Lower Genital Tract Disease, 2018, 22, 47-51.	1.9	7
32	Depth of Cervical Intraepithelial Neoplasia Grade 3 in Peruvian Women: Implications for Therapeutic Depth of Necrosis. Journal of Lower Genital Tract Disease, 2018, 22, 27-30.	1.9	6
33	Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records. Preventive Medicine, 2018, 111, 429-435.	3.4	15
34	Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the UK Clinical Practice Research Datalink. International Journal of Cancer, 2018, 142, 1174-1181.	5.1	25
35	Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer. Journal of Clinical Oncology, 2018, 36, 1184-1191.	1.6	65
36	Risk of Cervical Intraepithelial Neoplasia 2 or Worse by Cytology, Human Papillomavirus 16/18, and Colposcopy Impression. Obstetrics and Gynecology, 2018, 132, 725-735.	2.4	25

#	ARTICLE	IF	CITATIONS
37	Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer. <i>Annals of Internal Medicine</i> , 2018, 168, 20.	3.9	50
38	Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El Salvador. <i>Preventive Medicine</i> , 2018, 114, 149-155.	3.4	28
39	Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer. <i>International Journal of Cancer</i> , 2017, 141, 701-710.	5.1	62
40	Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2348-2355.	3.9	10
41	Cervical cancer prevention in El Salvador (CAPE) – An HPV testing-based demonstration project: Changing the secondary prevention paradigm in a lower middle-income country. <i>Gynecologic Oncology Reports</i> , 2017, 20, 58-61.	0.6	17
42	Considerations for HPV primary screening in lower-middle income countries. <i>Preventive Medicine</i> , 2017, 98, 39-41.	3.4	9
43	Evidence-Based Consensus Recommendations for Colposcopy Practice for Cervical Cancer Prevention in the United States. <i>Journal of Lower Genital Tract Disease</i> , 2017, 21, 216-222.	1.9	71
44	ASCCP Colposcopy Standards: Risk-Based Colposcopy Practice. <i>Journal of Lower Genital Tract Disease</i> , 2017, 21, 230-234.	1.9	56
45	Scale-Up of an Human Papillomavirus Testing Implementation Program in El Salvador. <i>Journal of Lower Genital Tract Disease</i> , 2017, 21, 26-32.	1.9	24
46	Diagnosis of Cervical Precancers by Endocervical Curettage at Colposcopy of Women With Abnormal Cervical Cytology. <i>Obstetrics and Gynecology</i> , 2017, 130, 1218-1225.	2.4	35
47	Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing. <i>JAMA Oncology</i> , 2017, 3, 1327.	7.1	13
48	Why does cervical cancer occur in a state-of-the-art screening program?. <i>Gynecologic Oncology</i> , 2017, 146, 546-553.	1.4	47
49	Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions. <i>Annals of Internal Medicine</i> , 2017, 166, 118.	3.9	53
50	Abstract A28: Risk model for clinical management of HPV-infected women. , 2017, , .		0
51	Introducing a High-Risk HPV DNA Test Into a Public Sector Screening Program in El Salvador. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 145-150.	1.9	17
52	Comparison of Colposcopic Impression Based on Live Colposcopy and Evaluation of Static Digital Images. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 154-161.	1.9	20
53	Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations. <i>Obstetrics and Gynecology</i> , 2016, 128, 1248-1257.	2.4	22
54	The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen. <i>Cancer</i> , 2016, 122, 3682-3686.	4.1	15

#	ARTICLE	IF	CITATIONS
55	A cohort study of cervical screening using partial HPV typing and cytology triage. International Journal of Cancer, 2016, 139, 2606-2615.	5.1	68
56	Risk assessment to guide cervical screening strategies in a large Chinese population. International Journal of Cancer, 2016, 138, 2639-2647.	5.1	16
57	World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. International Journal of Gynecology and Obstetrics, 2016, 132, 252-258.	2.3	134
58	Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 36-42.	2.5	14
59	Abstract CT111: Ablation techniques adapted for low- and middle-income countries. , 2016, , .		0
60	Abstract 2586: Evaluation of risk-based colposcopy in the ALTS trial. , 2016, , .		0
61	Factors affecting attendance to cervical cancer screening among women in the Paracentral Region of El Salvador: a nested study within the CAPE HPV screening program. BMC Public Health, 2015, 15, 1058.	2.9	17
62	The Value of Endocervical Curettage in Addition to Biopsies in Women Referred to Colposcopy. Journal of Lower Genital Tract Disease, 2015, 19, 282-287.	1.9	19
63	Squamous Intraepithelial Lesions in Cervical Tissue Samples of Limited Adequacy and Insufficient for Grading as Low or High Grade. Journal of Lower Genital Tract Disease, 2015, 19, 35-45.	1.9	6
64	The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador. International Journal of Cancer, 2015, 137, 893-902.	5.1	38
65	A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecologic Oncology, 2015, 138, 573-578.	1.4	49
66	The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1304-1310.	2.5	44
67	Comparison of Depth of Necrosis Using Cryotherapy by Gas and Number of Freeze Cycles. Journal of Lower Genital Tract Disease, 2015, 19, 1-6.	1.9	6
68	Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection. International Journal of Cancer, 2015, 136, 1665-1671.	5.1	39
69	A Study of Genotyping for Management of Human Papillomavirus-Positive, Cytology-Negative Cervical Screening Results. Journal of Clinical Microbiology, 2015, 53, 52-59.	3.9	89
70	The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management. Cancer Cytopathology, 2014, 122, 842-850.	2.4	25
71	Reassurance Against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test. Journal of the National Cancer Institute, 2014, 106, dju153-dju153.	6.3	200
72	Response. Journal of the National Cancer Institute, 2014, 107, dju390-dju390.	6.3	0

#	ARTICLE	IF	CITATIONS
73	Analytic and Clinical Performance of cobas HPV Testing in Anal Specimens from HIV-Positive Men Who Have Sex with Men. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2892-2897.	3.9	29
74	Acceptability of self-collected versus provider-collected sampling for HPV DNA testing among women in rural El Salvador. <i>International Journal of Gynecology and Obstetrics</i> , 2014, 126, 156-160.	2.3	52
75	Interrater agreement of anal cytology. <i>Cancer Cytopathology</i> , 2013, 121, 72-78.	2.4	46
76	Human papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta. <i>BMC Infectious Diseases</i> , 2013, 13, 5.	2.9	13
77	Plasma cytokine levels and human papillomavirus infection at the cervix in rural Nigerian women. <i>Cytokine</i> , 2013, 64, 146-151.	3.2	8
78	Human Papillomavirus Genotype Attribution and Estimation of Preventable Fraction of Anal Intraepithelial Neoplasia Cases Among HIV-Infected Men Who Have Sex With Men. <i>Journal of Infectious Diseases</i> , 2013, 207, 392-401.	4.0	56
79	Risk of Precancer Determined by HPV Genotype Combinations in Women with Minor Cytologic Abnormalities. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1095-1101.	2.5	24
80	A comparison of cervical histopathology variability using whole slide digitized images versus glass slides: experience with a statewide registry. <i>Human Pathology</i> , 2013, 44, 2542-2548.	2.0	19
81	A Population-Based Study of Visual Inspection With Acetic Acid (VIA) for Cervical Screening in Rural Nigeria. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 507-512.	2.5	47
82	Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, S28-S35.	1.9	167
83	Five-Year Risks of CIN 2+ and CIN 3+ Among Women With HPV-Positive and HPV-Negative LSIL Pap Results. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, S43-S49.	1.9	49
84	Five-Year Risks of CIN 3+ and Cervical Cancer Among Women Who Test Pap-Negative But Are HPV-Positive. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, S56-S63.	1.9	73
85	Comparative Risk of High-Grade Histopathology Diagnosis After a CIN 1 Finding in Endocervical Curettage Versus Cervical Biopsy. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, 137-141.	1.9	9
86	Five-Year Risk of Recurrence After Treatment of CIN 2, CIN 3, or AIS. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, S78-S84.	1.9	75
87	Follow-up Testing After Colposcopy. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, S69-S77.	1.9	59
88	Five-Year Risk of CIN 3+ to Guide the Management of Women Aged 21 to 24 Years. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, S64-S68.	1.9	28
89	Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, S36-S42.	1.9	85
90	Risk Factors for Anal HPV Infection and Anal Precancer in HIV-Infected Men Who Have Sex With Men. <i>Journal of Infectious Diseases</i> , 2013, 208, 1768-1775.	4.0	52

#	ARTICLE	IF	CITATIONS
91	Cervical Histopathology Variability Among Laboratories: A Population-Based Statewide Investigation. <i>American Journal of Clinical Pathology</i> , 2013, 139, 330-335.	0.7	28
92	Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV-Positive and HPV-Negative High-Grade Pap Results. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, S50-S55.	1.9	59
93	A Comparison of Human Papillomavirus Genotype-Specific DNA and E6/E7 mRNA Detection to Identify Anal Precancer among HIV-Infected Men Who Have Sex with Men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 42-49.	2.5	23
94	Clinical Human Papillomavirus Detection Forecasts Cervical Cancer Risk in Women Over 18 Years of Follow-Up. <i>Journal of Clinical Oncology</i> , 2012, 30, 3044-3050.	1.6	87
95	Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM. <i>Aids</i> , 2012, 26, 2185-2192.	2.2	70
96	World Health Organization Guidelines: Use of cryotherapy for cervical intraepithelial neoplasia. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 118, 97-102.	2.3	42
97	Comparison of the cobas Human Papillomavirus (HPV) Test with the Hybrid Capture 2 and Linear Array HPV DNA Tests. <i>Journal of Clinical Microbiology</i> , 2012, 50, 61-65.	3.9	47
98	Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. <i>International Journal of Cancer</i> , 2012, 131, 2903-2909.	5.1	51
99	A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. <i>BMC Infectious Diseases</i> , 2012, 12, 33.	2.9	96
100	The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: Implications for screen-and-treat strategies. <i>International Journal of Cancer</i> , 2012, 130, 2111-2117.	5.1	50
101	Human Papillomavirus Testing in the Prevention of Cervical Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 368-383.	6.3	583
102	Accepting the Universal Truths of Cervical Human Papillomavirus Epidemiology in Pursuit of the Remaining Mysteries. <i>Sexually Transmitted Diseases</i> , 2011, 38, 907-908.	1.7	1
103	The Clinical Meaning of a Cervical Intraepithelial Neoplasia Grade 1 Biopsy. <i>Obstetrics and Gynecology</i> , 2011, 118, 1222-1229.	2.4	35
104	A pilot analytic study of a research-level, lower-cost human papillomavirus 16, 18, and 45 test. <i>Journal of Virological Methods</i> , 2011, 176, 112-114.	2.1	4
105	A population-based cross-sectional study of age-specific risk factors for high risk human papillomavirus prevalence in rural Nigeria. <i>Infectious Agents and Cancer</i> , 2011, 6, 12.	2.6	23
106	Comparative Performance of Human Papillomavirus DNA Testing Using Novel Sample Collection Methods. <i>Journal of Clinical Microbiology</i> , 2011, 49, 4185-4189.	3.9	26
107	A Comparison of Dacron versus Flocked Nylon Swabs for Anal Cytology Specimen Collection. <i>Acta Cytologica</i> , 2011, 55, 364-367.	1.3	24
108	Detection of cervical cancer and its precursors by endocervical curettage in 13,115 colposcopically guided biopsy examinations. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 481.e1-481.e9.	1.3	48

#	ARTICLE	IF	CITATIONS
109	Comparison of Measurements of Human Papillomavirus Persistence for Postcolposcopic Surveillance for Cervical Precancerous Lesions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1668-1674.	2.5	20
110	Preventing Cervical Cancer Globally by Acting Locally: If Not Now, When?. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1524-1527.	6.3	18
111	Detection of Precancerous Cervical Lesions Is Differential by Human Papillomavirus Type. <i>Cancer Research</i> , 2009, 69, 3262-3266.	0.9	56
112	Treatability by Cryotherapy in a Screen-and-Treat Strategy. <i>Journal of Lower Genital Tract Disease</i> , 2009, 13, 174-181.	1.9	15
113	The Accuracy of Colposcopic Grading for Detection of High-Grade Cervical Intraepithelial Neoplasia. <i>Journal of Lower Genital Tract Disease</i> , 2009, 13, 137-144.	1.9	119
114	An Evaluation by Midwives and Gynecologists of Treatability of Cervical Lesions by Cryotherapy Among Human Papillomavirus-Positive Women. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 728-733.	2.5	6
115	Spectroscopic Imaging as Triage Test for Cervical Disease. <i>Journal of Lower Genital Tract Disease</i> , 2008, 12, 52-53.	1.9	2
116	Number of Cervical Biopsies and Sensitivity of Colposcopy. <i>Obstetrics and Gynecology</i> , 2006, 108, 264-272.	2.4	289
117	Assuring Adequate Health Insurance: Results of the National Survey of Children With Special Health Care Needs. <i>Pediatrics</i> , 2005, 115, 1233-1239.	2.1	51
118	Peer activity in the evenings and participation in aggressive and problem behaviors. <i>Journal of Adolescent Health</i> , 2005, 37, 517.e7-517.e14.	2.5	40
119	Follow-up care of women with an abnormal cytology in a low-resource setting. <i>Cancer Detection and Prevention</i> , 2003, 27, 466-471.	2.1	73